Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2023-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
独立董事候选人声明（裴端卿）
Regulatory Filings Classification · 95% confidence The document text is largely garbled and nonsensical, containing no recognizable financial, regulatory, or corporate reporting content. There are no references to any specific report types, fiscal periods, regulatory bodies, or corporate events. The length is short (1708 characters) and does not contain substantive financial data or meaningful text. Given the lack of any identifiable content, the document does not fit any specific filing category and should be classified as a Regulatory Filing (RNS), which serves as a fallback category for miscellaneous or unclear filings.
2023-04-25 Chinese
中源协和细胞基因工程股份有限公司2022年年度报告
Annual Report Classification · 100% confidence The document is titled "2022 年年度报告" which translates to "2022 Annual Report". It contains detailed financial data, management discussion and analysis, company overview, governance, environmental and social responsibility sections, and an auditor's report with an unqualified opinion. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes comprehensive financial statements, management commentary, risk disclosures, and operational details typical of an annual report. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K).
2023-04-25 Chinese
中源协和细胞基因工程股份有限公司关于召开2022年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2022 Annual General Meeting (AGM) of the company 中源协和细胞基因工程股份有限公司. It includes information about the date, voting methods, meeting agenda, and instructions for shareholders to participate and vote. It does not contain the actual annual report or financial statements but rather the announcement and procedural details for the AGM. The document length is 4390 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-04-25 Chinese
中源协和细胞基因工程股份有限公司2022年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2022 Annual Report on the Deposit and Actual Use of Raised Funds" by the company 中源协和细胞基因工程股份有限公司. It details the amount of funds raised, their usage, management, and compliance with regulatory requirements. It includes tables showing the use of funds, changes in investment projects, and auditor and sponsor opinions on the use of funds. The document is a specialized report focused on the management and use of capital raised by the company, not a general annual report or earnings release. It is not a simple announcement or certification but contains substantive financial and operational data related to fundraising and capital use. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure usage.
2023-04-25 Chinese
中源协和细胞基因工程股份有限公司独立董事关于2022年度利润分配预案的独立意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing their independent opinion on the company's 2022 profit distribution plan. It references compliance with regulatory rules and company bylaws, and it is a formal opinion rather than the profit distribution plan itself or the official announcement of dividend amounts. The document is very short (407 characters) and does not contain financial data or dividend payment details. It is not a full report or announcement of dividend amounts but an independent opinion related to the profit distribution plan. Therefore, it does not fit into categories like DIV (Notice of Dividend Amount) or 10-K (Annual Report). It is best classified under Regulatory Filings (RNS) as a formal regulatory document that does not fit other specific categories.
2023-04-25 Chinese
中源协和细胞基因工程股份有限公司关于控股股东一致行动人部分股权质押延期的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the extension of a share pledge by the controlling shareholder and related parties. It details the number of shares pledged, the pledge extension dates, and the purpose of the pledge. There is no financial statement, management discussion, or detailed report content. The document is relatively short (2599 characters) and serves as a disclosure of a specific financing-related event concerning share pledges. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2023-04-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.